Choosing a phase I design

Handbook of Statistics in Clinical Oncology: Second Edition

Volumn , Issue , 2005, Pages 59-75

  Storer, Barry E ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951617401     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (18)

1. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical studies in cancer. Biometrics 1990;46:33-18.
2. O'Quigley J, Chevret S. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Statistics in Medicine 1991; 10:1647-1664.
3. Shen LZ, O'Quigley J. Consistency of continual reassessment method under model misspecification. Biometrika 1996;83:395-105.
4. Gatsonis C, Greenhouse JB. Bayesian methods for phase I clinical trials. Statistics in Medicine 1992;11:1377-1389.
5. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996;52:673-684.
6. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1995; 14:1149-1161.
7. Heyd JM, Carlin BP. Adaptive design improvements in the continual reassessment method for phase I studies. Statistics in Medicine 1999;18:1307-1321.
8. Piantadosi S, Liu G. Improved designs for dose escalation studies using pharmacokinetic measurements. Statistics in Medicine 1996;15:1142-1149.
9. Storer B. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.
10. Storer B. Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics 1993;49:1117-1125.
11. Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G. Phase I clinical and pharmacokinetic trial of penclomedine utilizing a novel, two-stage trial design. Journal of Clinical Oncology 1998; 16:1142-1149.
12. Eichhorn BH, Zacks S. Sequential search of an optimal dosage. Journal of the American Statistical Association 1973;68:594-598.
13. Mick R, Ratain MJ. Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. Journal of the National Cancer Institute 1993;85:217-223.
14. Anbar D. Stochastic approximation methods and their use in bioassay and phase I clinical trials. Communications in Statistics: Theory and Methods 1984; 13:2451-2467.
15. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: efficient dose escalation with overdose control. Statistics in Medicine 1996;17:1103-1120.
16. Storer B. An evaluation of phase I designs for continuous dose response. Statistics in Medicine 2001;20:2399-2408.
17. Korn EL, Midthure D, Chen TT, Rubinstein LV, Christian MC, Simon R. A comparison of two phase I trial designs. Statistics in Medicine 1994;13:1799-1806.
18. Ahn C. An evaluation of phase I cancer clinical trial designs. Statistics in Medicine 1998;17:1537-1549.